Trial Information
Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer
Inclusion Criteria:
- Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not
metastasized, or spread to other parts of the body, are eligible for the study.
- Participants must have had either a core biopsy or incisional biopsy of their breast
cancer, but not yet had definitive breast surgery, including lumpectomy or
mastectomy.
- Participants may not have had a BRCA mutation found on genetic testing.
- Participants should have not yet received treatment for their breast cancer,
including:
- chemotherapy,
- hormonal therapy,
- trastuzumab.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To see if treatment with trastuzumab can make ER appear in ER "negative" breast cancer.Trastuzumab is an anti-Her-2 drug usually given after surgery for treatment of Her-2 "positive" breast cancer.
Outcome Time Frame:
90 days
Safety Issue:
No
Principal Investigator
Anne Schott, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Michigan Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
UMCC 2007.130
NCT ID:
NCT00726180
Start Date:
July 2008
Completion Date:
October 2010
Related Keywords:
- Breast Cancer
- Breast cancer
- Women
- w/Her2
- positive
- ERnegative
- not metastasized
- Breast Neoplasms
Name | Location |
University of Michigan Comprehensive Cancer Center |
Ann Arbor, Michigan 48109-0752 |